The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?
Open accessThe DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Abstract
Immune-checkpoint inhibitors (ICI) now represent the standard of care for several cancer types. In pre-clinical models, absence of an intact gut microbiome negatively impacted ICI efficacy and these findings permitted to unravel the importance of the commensal microbiota in immuno-oncology. Recently, multiple clinical studies including more than 1800 patients in aggregate demonstrated the negative predictive impact of treatments with broad-spectrum antibiotics (ATB) on cancer patients receiving ICI. Altogether, these results have led to the hypothesis that ATB-induced dysbiosis might influence the clinical response through the modulation of the gut microbiome. Controversy still remains, as ATB treatment might simply constitute a surrogate marker of unfit or immunodeficient patients. In this review, we summarize recent publications addressing the impact of the gut microbiome on ICI efficacy, discuss currently available data on the effect of ATB administered in different time-frames respect to ICI initiation, and finally, evoke the therapeutic implications of these findings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Apart from Akk, very few bacteria (except Eubacterium hallii, Bifidobacterium adolescentis, Parasutterella excrementihominis, Intestinimonas butyriciproducens, or C. innocuum already described to mediate immunomodulatory functions [43][44][45] were also associated with prolonged (Figure 3B, Figure 3D) or reduced survival following ICI therapy (Figure 3F, Table S6)”
From Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer (2022) · cites this paper as [43]
In the citing paper
“First, antibiotic use near the start of ICB therapy is linked to worse outcomes.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Elkrief et al., 2019
Citations
Cites
1 retracted
Lagier, J.-C., Khelaifia, S., Alou, M. T., Ndongo, S., Dione, N., Hugon, P., Caputo, A., Cadoret, F., Traore, S. I., Seck, E. H., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.203 · Cited by 951
RetractedImproved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
Self-citationThe human microbiome: at the interface of health and disease
Cho, I., & Blaser, M. J. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3182 · Cited by 3,449
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., Qian, Y., Kryczek, I., Sun, D., Nagarsheth, N., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.008 · Cited by 2,198
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Self-citationGeller, L. T., Barzily-Rokni, M., Danino, T., Jonas, O. H., Shental, N., Nejman, D., Gavert, N., Zwang, Y., Cooper, Z. A., Shee, K., et al. (2017) · Science · doi:10.1126/science.aah5043 · Cited by 1,817
Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer
Bullman, S., Pedamallu, C. S., Sicinska, E., Clancy, T. E., Zhang, X., Cai, D., Neuberg, D., Huang, K., Guevara, F., Nelson, T., et al. (2017) · Science · doi:10.1126/science.aal5240 · Cited by 1,574
Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A., Bataller, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.007 · Cited by 1,346
The microbiome in early life: Implications for health outcomes
Tamburini, S., Shen, N., Wu, H. C., & Clemente, J. C. (2016) · Nature Medicine · doi:10.1038/nm.4142 · Cited by 1,213
Suez, J., Zmora, N., Zilberman-Schapira, G., Mor, U., Dori-Bachash, M., Bashiardes, S., Zur, M., Regev-Lehavi, D., Ben-Zeev Brik, R., Federici, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.047 · Cited by 1,184
A defined commensal consortium elicits CD8 T cells and anti-cancer immunity
Tanoue, T., Morita, S., Plichta, D. R., Skelly, A. N., Suda, W., Sugiura, Y., Narushima, S., Vlamakis, H., Motoo, I., Sugita, K., et al. (2019) · Nature · doi:10.1038/s41586-019-0878-z · Cited by 1,145
Arbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., Martínez-Bernal, G., Ferrara, R., Lai, W. V., Hendriks, L. E. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0006 · Cited by 1,071
Derosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy103 · Cited by 908
Self-citationDaillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., Duong, C. P. M., Flament, C., Lepage, P., Roberti, M. P., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.009 · Cited by 897
Self-citationTaur, Y., Jenq, R. R., Perales, M.-A., Littmann, E. R., Morjaria, S., Ling, L., No, D., Gobourne, A., Viale, A., Dahi, P. B., et al. (2014) · Blood · doi:10.1182/blood-2014-02-554725 · Cited by 885
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1509660 · Cited by 872
Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease
Jenq, R. R., Taur, Y., Devlin, S. M., Ponce, D. M., Goldberg, J. D., Ahr, K. F., Littmann, E. R., Ling, L., Gobourne, A. C., Miller, L. C., et al. (2015) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2015.04.016 · Cited by 748
Shono, Y., Docampo, M. D., Peled, J. U., Perobelli, S. M., Velardi, E., Tsai, J. J., Slingerland, A. E., Smith, O. M., Young, L. F., Gupta, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2311 · Cited by 592
Anticancer effects of the microbiome and its products
Zitvogel, L., Daillère, R., Roberti, M. P., Routy, B., & Kroemer, G. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.44 · Cited by 538
Self-citationAntibiotics, Pediatric Dysbiosis, and Disease
Vangay, P., Ward, T., Gerber, J. S., & Knights, D. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.04.006 · Cited by 530
The gut microbiota influences anticancer immunosurveillance and general health
Routy, B., Gopalakrishnan, V., Daillère, R., Zitvogel, L., Wargo, J. A., & Kroemer, G. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0006-2 · Cited by 523
Self-citationChemotherapy‐driven dysbiosis in the intestinal microbiome
Montassier, E., Gastinne, T., Vangay, P., Al‐Ghalith, G. A., Bruley des Varannes, S., Massart, S., Moreau, P., Potel, G., de La Cochetière, M. F., Batard, E., et al. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13302 · Cited by 515
Crenn, P., Coudray–Lucas, C., Thuillier, F., Cynober, L., & Messing, B. (2000) · Gastroenterology · doi:10.1053/gast.2000.20227 · Cited by 498
Reshaping the gut microbiome with bacterial transplantation and antibiotic intake
Manichanh, C., Reeder, J., Gibert, P., Varela, E., Llopis, M., Antolin, M., Guigo, R., Knight, R., & Guarner, F. (2010) · Genome Research · doi:10.1101/gr.107987.110 · Cited by 335
Antibiotic Use in Relation to the Risk of Breast Cancer
Velicer, C. M. (2004) · JAMA · doi:10.1001/jama.291.7.827 · Cited by 331
Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation
Peled, J. U., Devlin, S. M., Staffas, A., Lumish, M., Khanin, R., Littmann, E. R., Ling, L., Kosuri, S., Maloy, M., Slingerland, J. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3348 · Cited by 325
Rutkowski, M. R., Stephen, T. L., Svoronos, N., Allegrezza, M. J., Tesone, A. J., Perales-Puchalt, A., Brencicova, E., Escovar-Fadul, X., Nguyen, J. M., Cadungog, M. G., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.009 · Cited by 311
Escudier, B., Sharma, P., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.02.010 · Cited by 256
Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity
DeFilipp, Z., Peled, J. U., Li, S., Mahabamunuge, J., Dagher, Z., Slingerland, A. E., Del Rio, C., Valles, B., Kempner, M. E., Smith, M., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018017731 · Cited by 211
Elkrief, A., El Raichani, L., Richard, C., Messaoudene, M., Belkaid, W., Malo, J., Belanger, K., Miller, W., Jamal, R., Letarte, N., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1568812 · Cited by 208
Self-citationUsing Corticosteroids to Reshape the Gut Microbiome: Implications for Inflammatory Bowel Diseases
Huang, E. Y., Inoue, T., Leone, V. A., Dalal, S., Touw, K., Wang, Y., Musch, M. W., Theriault, B., Higuchi, K., Donovan, S., et al. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000332 · Cited by 204
Cheng, M., Qian, L., Shen, G., Bian, G., Xu, T., Xu, W., Shen, G., & Hu, S. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2462 · Cited by 182
Ahmed, J., Kumar, A., Parikh, K., Anwar, A., Knoll, B. M., Puccio, C., Chun, H., Fanucchi, M., & Lim, S. H. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1507670 · Cited by 171
Staffas, A., Burgos da Silva, M., Slingerland, A. E., Lazrak, A., Bare, C. J., Holman, C. D., Docampo, M. D., Shono, Y., Durham, B., Pickard, A. J., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.03.002 · Cited by 143
Antibiotic use predicts an increased risk of cancer
Kilkkinen, A., Rissanen, H., Klaukka, T., Pukkala, E., Heliövaara, M., Huovinen, P., Männistö, S., Aromaa, A., & Knekt, P. (2008) · International Journal of Cancer · doi:10.1002/ijc.23622 · Cited by 122
Non-invasive markers of gut wall integrity in health and disease
Derikx, J. P. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i42.5272 · Cited by 114
Antibiotic Use Does Not Appear to Influence Response to Nivolumab
(2017) · Anticancer Research · doi:10.21873/anticanres.11680 · Cited by 107
Impact of antibiotic exposure on the risk of colorectal cancer: ANTIBIOTIC EXPOSURE AND CRC RISK
Boursi, B., Haynes, K., Mamtani, R., & Yang, Y.-X. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3765 · Cited by 89
Huemer, F., Rinnerthaler, G., Westphal, T., Hackl, H., Hutarew, G., Gampenrieder, S. P., Weiss, L., & Greil, R. (2018) · Oncotarget · doi:10.18632/oncotarget.24751 · Cited by 87
Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy
Hussain, M., Javeed, A., Ashraf, M., Al-Zaubai, N., Stewart, A. G., & Mukhtar, M. M. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.02.003 · Cited by 81
Antibiotics and Risk of Breast Cancer: Up to 9 Years of Follow-up of 2.1 Million Women
Friedman, G. D., Oestreicher, N., Chan, J., Quesenberry, C. P., Udaltsova, N., & Habel, L. A. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0401 · Cited by 77
Partial recovery of microbiomes after antibiotic treatment
Raymond, F., Déraspe, M., Boissinot, M., Bergeron, M. G., & Corbeil, J. (2016) · Gut Microbes · doi:10.1080/19490976.2016.1216747 · Cited by 64
Antibiotic Use and the Risk of Lung Cancer
Zhang, H., Rodríguez, L. A. G., & Hernández–Díaz, S. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-2817 · Cited by 57
Frequent Antibiotic Use and Second Breast Cancer Events
Wirtz, H. S., Buist, D. S. M., Gralow, J. R., Barlow, W. E., Gray, S., Chubak, J., Yu, O., Bowles, E. J. A., Fujii, M., & Boudreau, D. M. (2013) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0454 · Cited by 40
Homicsko, K., Richtig, G., Tuchmann, F., Tsourti, Z., Hanahan, D., Coukos, G., Wind-Rotolo, M., Richtig, E., Zygoura, P., Holler, C., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy511.001 · Cited by 38
Mielgo-Rubio, X., Chara, L. E., Sotelo-Lezama, M. J., Castro, R. L., Rubio-Martínez, J., Velástegui, A., Olier, C., Falagán, S., Gómez-Barreda, I., Bautista-Sanz, P., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.395 · Cited by 30
Tinsley, N., Zhou, C., Villa, S., Tan, G., Lorigan, P., Blackhall, F. H., Elliott, T., Krebs, M., Carter, L., Thistlethwaite, F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3010 · Cited by 26
Association between antibiotic use and risk of prostate cancer
Tamim, H., Hajeer, A. H., Boivin, J., & Collet, J. (2009) · International Journal of Cancer · doi:10.1002/ijc.25139 · Cited by 22
Antibiotic use and overall survival in lung cancer patients receiving nivolumab.
Do, T. P., Hegde, A. M., Cherry, C. R., Stroud, C. R. G., Sharma, N., Cherukuri, S. D., Bowling, M., & Walker, P. R. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e15109 · Cited by 21
Effects of antibiotic use during immunotherapy in metastatic non-small cell lung cancer
Galli, G., Poggi, M. M., Fucà, G., Imbimbo, M., Proto, C., Signorelli, D., Vitali, M., Zilembo, N., Ganzinelli, M., de Braud, F., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy292.088 · Cited by 11
Ouaknine, J., de Tauriers, P. H., Duménil, C., Neveux, N., Dumoulin, J., Giraud, V., Labrune, S., Tisserand, J. C., Emile, J., Chinet, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.397 · Cited by 7
Tan, W. W., Hillman, D. W., Salim, M., Northfelt, D., Anderson, D. M., Stella, P. J., Niedringhaus, R. D., Bernath, A. M., Soori, G. S., Palmieri, F. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx811 · Cited by 7
Cited by
The cancer-immunity cycle: Indication, genotype, and immunotype
Mellman, I., Chen, D. S., Powles, T., & Turley, S. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.011 · Cited by 953
Bender, M. J., McPherson, A. C., Phelps, C. M., Pandey, S. P., Laughlin, C. R., Shapira, J. H., Medina Sanchez, L., Rana, M., Richie, T. G., Mims, T. S., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.011 · Cited by 732
“19 Given antibiotic (ABX) treatment negatively impacts responses to cancer immunotherapy 11,12,16,20 and probiotics are typically supplemented daily, 19 we treated non-ABX-treated specific-pathogen-free (SPF) mice with selected bacterial taxa via daily oral gavage (OG).”
Derosa, L., Routy, B., Thomas, A. M., Iebba, V., Zalcman, G., Friard, S., Mazieres, J., Audigier-Valette, C., Moro-Sibilot, D., Goldwasser, F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01655-5 · Cited by 685
Self-citationCullin, N., Azevedo Antunes, C., Straussman, R., Stein-Thoeringer, C. K., & Elinav, E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.006 · Cited by 578
CD8+ T cells in the cancer-immunity cycle
Giles, J. R., Globig, A.-M., Kaech, S. M., & Wherry, E. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.005 · Cited by 449
Metadata
- Authors
- Elkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., & Routy, B.
- Affiliations
- McGill University Health Centre (CA)
- Inserm (FR)
- Karolinska University Hospital (SE)
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Routy, B.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 30
- Issue
- 10
- Pages
- 1572-1579
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2955224282
- Cited by
- 246
- References
- 66
- Citations by year
- 2026: 22 · 2025: 35 · 2024: 26 · 2023: 42 · 2022: 36 · 2021: 44 · 2020: 36 · 2019: 5
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 366 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Montreal Cancer Institute
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Keywords
- broad-spectrum antibiotics, immune checkpoint inhibitors, gut microbiota, dysbiosis, cancer immunotherapy, prognostic factors, immunotherapy response, immunodeficiency
- MeSH terms
- Gastrointestinal Microbiome, Antineoplastic Agents, Immunological, Anti-Bacterial Agents, Humans, Immunotherapy, Neoplasms, Prognosis, Survival Rate, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.